Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Poddubskaya E. V., Baranova M. P., Allina D. O., Smirnov P. Y., Al`bert E. A., Kirilchev A. P., Aleshin A. A., Sekacheva M. I., Suntsova M. V.
Experimental Hematology and Oncology
Vol.7, Issue1, Num.21
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.1186/s40164-018-0113-x
Аннотация:
Background: Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at the stage of the diagnosis and the best clinical practice chemotherapy results in about 12-month median survival. Several tyrosine kinase inhibitors (TKIs) are currently under investigation as an alternative treatment option for cholangiocarcinoma. Thus, the report of personalized selection of effective inhibitor and case outcome are of clinical interest. Case presentation: Here we report a case of aggressive metastatic cholangiocarcinoma (MCC) in 72-year-old man, sequentially treated with two targeted chemotherapies. Initially disease quickly progressed during best clinical practice care (gemcitabine in combination with cisplatin or capecitabine), which was accompanied by significant decrease of life quality. Monotherapy with TKI sorafenib was prescribed to the patient, which resulted in stabilization of tumor growth and elimination of pain. The choice of the i
Ключевые слова:
capecitabine; cisplatin; fentanyl; gemcitabine; ketorolac trometamol; pazopanib; sorafenib; tramadol; aged; analgesia; Article; bile duct carcinoma; cancer combination chemotherapy; cancer survival; case report; cause of death; clinical article; clinical feature; drug choice; drug effect; drug safety; drug substitution; drug withdrawal; gene expression; hand foot syndrome; high throughput screening; human; human tissue; liver failure; male; median survival time; metastatic cholangiocarcinoma; monotherapy; nuclear magnetic resonance imaging; outcome assessment; pain; personalized medicine; prescription; priority journal; quality of life; rash; treatment planning; tumor biopsy
Язык текста: Английский
ISSN: 2162-3619
Poddubskaya E. V. Elena Vladimirovna 1965-
Baranova M. P.
Allina D. O.
Smirnov P. Y.
Al`bert E. A. Evgenij Aleksandrovich 1989-
Kirilchev A. P.
Aleshin A. A.
Sekacheva M. I. Marina Igorevna 1976-
Suntsova M. V. Mariya Vladimirovna 1986-
Поддубская Е. В. Елена Владимировна 1965-
Баранова М. П.
Аллина Д. О.
Смирнов П. Y.
Альберт Е. А. Евгений Александрович 1989-
Кирилчев А. П.
Алешин А. А.
Секачева М. И. Марина Игоревна 1976-
Сунцова М. В. Мария Владимировна 1986-
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Текст визуальный непосредственный
Experimental Hematology and Oncology
Vol.7, Issue1 Num.21
2018
Статья
capecitabine cisplatin fentanyl gemcitabine ketorolac trometamol pazopanib sorafenib tramadol aged analgesia Article bile duct carcinoma cancer combination chemotherapy cancer survival case report cause of death clinical article clinical feature drug choice drug effect drug safety drug substitution drug withdrawal gene expression hand foot syndrome high throughput screening human human tissue liver failure male median survival time metastatic cholangiocarcinoma monotherapy nuclear magnetic resonance imaging outcome assessment pain personalized medicine prescription priority journal quality of life rash treatment planning tumor biopsy
Background: Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at the stage of the diagnosis and the best clinical practice chemotherapy results in about 12-month median survival. Several tyrosine kinase inhibitors (TKIs) are currently under investigation as an alternative treatment option for cholangiocarcinoma. Thus, the report of personalized selection of effective inhibitor and case outcome are of clinical interest. Case presentation: Here we report a case of aggressive metastatic cholangiocarcinoma (MCC) in 72-year-old man, sequentially treated with two targeted chemotherapies. Initially disease quickly progressed during best clinical practice care (gemcitabine in combination with cisplatin or capecitabine), which was accompanied by significant decrease of life quality. Monotherapy with TKI sorafenib was prescribed to the patient, which resulted in stabilization of tumor growth and elimination of pain. The choice of the i